Revenue Performance - Revenue increased by 3% to $203.0 million from $197.9 million[102] - Total revenue for Q1 2025 was $202.97 million, a 1.1% increase from $197.88 million in Q1 2024[120] - Prescription transactions revenue increased by $3.5 million, or 2%, year-over-year, totaling $148.92 million in Q1 2025[123] - Subscription revenue decreased by $1.6 million, or 7%, year-over-year, totaling $21.02 million in Q1 2025[124] - Pharma manufacturer solutions revenue increased by $4.1 million, or 17%, year-over-year, totaling $28.65 million in Q1 2025[125] Profitability - Net income was $11.1 million with a net income margin of 5.4%, compared to a net loss of $1.0 million and a net loss margin of 0.5% in the previous year[102] - Operating income for Q1 2025 was $23.38 million, compared to $7.38 million in Q1 2024[122] - Net income for Q1 2025 was $11.05 million, a significant improvement from a net loss of $1.01 million in Q1 2024[122] - Adjusted EBITDA rose to $69.8 million, with an Adjusted EBITDA Margin of 34.4%, up from $62.8 million and 31.7% respectively[102] Consumer Metrics - Monthly Active Consumers decreased to 6.4 million in Q1 2025 from 6.7 million in Q1 2024[106] - Subscription plans totaled 680,000 as of March 31, 2025, down from 778,000 a year earlier[108] - The company expects a year-over-year decline in Monthly Active Consumers in the near term due to changes in retail pharmacy reimbursement models[105] Cash Flow and Financial Position - Cash and cash equivalents as of March 31, 2025, were $301.0 million, with $91.7 million available under a revolving credit facility[135] - Net cash provided by operating activities decreased by $33.2 million year-over-year, totaling $9.41 million in Q1 2025[142] - Net cash used in investing activities increased by $31.3 million year-over-year, primarily due to a $30.0 million increase in cash paid for business acquisition[143] - General and administrative expenses decreased by $11.5 million, or 28%, year-over-year, totaling $29.63 million in Q1 2025[130] Strategic Outlook - Revenue from Rite Aid is forecasted to be less than 5% of total revenue in 2025 due to store closures and bankruptcy proceedings[100] - The company aims to build a leading consumer-focused digital healthcare platform in the U.S. to address rising copays on prescription medications[99] - The company anticipates that prescription volume will migrate to other in-network pharmacies despite the adverse impact from retail pharmacy changes[100] - Adjusted Revenue for Q1 2025 was equal to reported revenue, excluding client contract termination costs[110]

Revenue Performance - First Quarter 2025 revenue increased by 3% to $203.0 million compared to $197.9 million in the same period last year[3] - Total revenue for Q1 2025 was $202.97 million, up 2.2% from $197.88 million in Q1 2024[30] - Revenue for Q1 2025 was $202,970,000, a 1.1% increase from $197,880,000 in Q1 2024[45] - For the full year 2025, the company anticipates revenue between $810 million and $840 million, representing a 2% to 6% growth compared to 2024[12] Segment Performance - Prescription transactions revenue rose by 2% to $148.9 million, driven by improved unit economics, despite a 4% decrease in Monthly Active Consumers[4] - Subscription revenue decreased by 7% to $21.0 million, primarily due to the discontinuation of the Kroger Savings Club partnership[5] - Pharma manufacturer solutions revenue increased by 17% to $28.6 million, reflecting organic growth and expanded market penetration[6] Profitability Metrics - Net income for the first quarter was $11.1 million, with a net income margin of 5.4%, compared to a net loss of $1.0 million in the prior year[6] - Net income for Q1 2025 was $11.05 million, a significant improvement from a net loss of $1.01 million in Q1 2024[30] - Adjusted Net Income for Q1 2025 was $34,363,000, compared to $32,586,000 in Q1 2024, showing a year-over-year increase of 5.4%[45] - Basic earnings per share for Q1 2025 was $0.03, compared to $(0.00) in Q1 2024, indicating a positive shift in profitability[45] Operational Efficiency - Adjusted EBITDA was $69.8 million, with an Adjusted EBITDA margin of 34.4%, up from 31.7% in the previous year[7] - Adjusted EBITDA for Q1 2025 reached $69,805,000, up from $62,787,000 in Q1 2024, indicating a growth of approximately 16%[42] - Adjusted EBITDA margin for Q1 2025 was 34.4%, up from 31.7% in Q1 2024, reflecting improved operational efficiency[42] - Operating income for Q1 2025 was $23.38 million, compared to $7.38 million in Q1 2024, an increase of 216.5%[30] - Operating income for Q1 2025 was $23,380,000, significantly higher than $7,381,000 in Q1 2024, indicating strong operational performance[49] Cash Flow and Assets - Cash flow from operating activities was $9.4 million, down from $42.6 million in the same quarter last year[8] - Cash and cash equivalents decreased to $300.98 million as of March 31, 2025, down from $448.35 million at the end of 2024, a reduction of 32.9%[27] - Total assets decreased to $1.30 billion in March 2025 from $1.39 billion in December 2024, a decline of 6.7%[27] - Total liabilities decreased to $640.92 million in March 2025 from $663.41 million in December 2024, a reduction of 3.4%[28] Consumer Metrics - The company exited the first quarter with over 7 million prescription-related consumers using GoodRx services[24] - Monthly Active Consumers decreased to 6.4 million in March 2025 from 6.6 million in December 2024, representing a decline of 3%[25] - Subscription plans decreased to 680,000 in March 2025 from 778,000 in March 2024, a decline of 12.6%[25] Cost Management - Total stock-based compensation expense for Q1 2025 was $19,174,000, down from $25,096,000 in Q1 2024, suggesting cost management efforts[45] - General and administrative expenses decreased to $29,630,000 in Q1 2025 from $41,108,000 in Q1 2024, representing a reduction of approximately 28%[47] Acquisition Costs - The company incurred $30 million in acquisition costs during Q1 2025[32] Future Guidance - Adjusted EBITDA guidance for 2025 is now between $273 million and $287 million, indicating a 5% to 10% growth compared to the previous year[12] - Adjusted EBITDA for Q1 2025 is expected to align with revenue, indicating stable operational performance moving forward[34]

Group 1 - Value stocks have lost favor as investors focus on high-growth stocks, particularly those linked to the AI industry [1] - There is a notable decline in valuation multiples due to concerns about a potential U.S. recession [1] - Gary Alexander has extensive experience in technology sectors, both on Wall Street and in Silicon Valley, influencing current industry themes [1]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-K __________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____. Commission File Number: 001-3 ...

GoodRx Holdings Inc. GDRX reported fourth-quarter revenue of $198.6 million, up slightly by 1% year over year, missing the management guidance of around $200 million and consensus of $199.75 million.Fiscal year sales of $792.3 million came in below the guidance of around $794 million.The company reported adjusted EPS of 9 cents, up from 8 cents a year ago, missing the consensus of 10 cents.Q4 prescription transactions revenue increased 0.8% to $144.9 million. 2024 prescription transactions revenue increased ...

GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Aubrey Reynolds - Director, IR Wendy Barnes - CEO Chris McGinnis - CFO Conference Call Participants Lisa Gill - J.P. Morgan John Ransom - RJF Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jenny Cao - Truist Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Securities Steven Valiquette - Mizuho Securities Jay Jin - Morgan Stanley George Hill - Deutsche Bank Allen Lutz - ...

For the quarter ended December 2024, GoodRx Holdings, Inc. (GDRX) reported revenue of $198.58 million, up 1% over the same period last year. EPS came in at $0.09, compared to $0.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $199.81 million, representing a surprise of -0.62%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Financial Data and Key Metrics Changes - For Q4 2024, revenue was $198.6 million, and adjusted EBITDA was $67.1 million, leading to a full year revenue of $792.3 million, a 6% increase year-over-year on a GAAP basis [29] - Full year adjusted EBITDA was $260.2 million, representing a 20% growth over 2023 [30] - Net income for 2024 was $16.4 million compared to a net loss of $8.9 million in 2023, while adjusted net income increased to $131.6 million from $114.6 million in 2023 [30][31] - Adjusted EBITDA margin improved to 32.8%, marking another year of margin expansion [30][32] Business Line Data and Key Metrics Changes - Prescription transactions revenue grew 5% year-over-year to $577.5 million, primarily due to a 7% increase in monthly active consumers [29][30] - Subscription revenue declined 8% to $86.5 million, largely due to the sunset of a retailer-specific prescription savings program [30] - Pharma manufacturer solutions revenue increased by 26% year-over-year to $107.2 million [30] Market Data and Key Metrics Changes - Nearly 30 million consumers used GoodRx in 2024, saving approximately $17 billion on medications, with a 3% year-over-year growth in the prescription discount segment [14][29] - The company's share of the prescription discount segment grew by 3% year-over-year in Q4 2024 [14] Company Strategy and Development Direction - The company aims to enhance the prescription experience for consumers and healthcare professionals, focusing on reducing friction and improving access to medications [10][12] - GoodRx is expanding its Integrated Savings Program (ISP) to include non-covered brands, addressing gaps in coverage and enhancing value for consumers and healthcare professionals [17][25] - The company is also increasing its partnerships with pharma manufacturers, growing from 150 to over 200 brands in 2024, and focusing on integrated access solutions and e-commerce capabilities [18][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the opportunities to make healthcare more affordable and accessible, particularly in light of potential regulatory changes favoring transparency and lower prices [13][28] - The company anticipates revenue growth in 2025 to be in the range of $810 million to $840 million, representing approximately 4% growth at the midpoint [33] - Management acknowledged potential headwinds from pharmacy store closures but remains confident in the overall growth trajectory of prescription transaction revenue [102] Other Important Information - The company has a strong balance sheet with $448.3 million in cash on hand and $500 million in outstanding debt, providing significant liquidity [32] - GoodRx is committed to returning excess cash to shareholders through share repurchases, with $290 million authorized for spend [75] Q&A Session Summary Question: How many new initiatives are included in the guidance? - Management indicated that the guidance accounts for some expansion in manufacturer programs and marketplace growth, particularly in brand expansion [39][40] Question: Can you comment on the pharma manufacturing solutions growth? - Management remains confident in achieving 20% growth in pharma manufacturer solutions, citing a significant increase in partnerships and validated results [48][49] Question: What is the current status of ISP rollouts with PBM partners? - Management noted ongoing discussions with PBM partners and emphasized the importance of wrapping non-covered brands to enhance value [56][58] Question: What are the headwinds reflected in the guidance? - Management acknowledged potential headwinds from pharmacy store closures but expects overall growth in prescription transaction revenue [102]

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.08, delivering a surprise of -11.11%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.GoodRx, which belon ...

Exhibit 99.1 GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance SANTA MONICA, Calif. -- (February 27, 2025) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Full Year 2024 Highlights "I am excited to join GoodRx ...